Targeting the ST3 beta‐galactoside alpha‐2,3‐sialyltransferase 1 (ST3Gal1) as a potential therapeutic strategy to overcome anti‐VEGF resistance in endometrial cancer. Here, VEGFA is linked to endometrial cancer.